Structure-activity relationships in platelet-activating factor (PAF).7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonist activity
Le Texier, Laurence; Favre, Edith; Redeuilh, Catherineet al.
1996 • In Journal of Lipid Mediators and Cell Signalling, 13, p. 189-205
Dive, Georges ; Université de Liège - ULiège > Centre d'ingénierie des protéines
Pirotzky, Edouardo
Godfroid, Jean-Jacques
Language :
English
Title :
Structure-activity relationships in platelet-activating factor (PAF).7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonist activity
Lawley, K.P. (1985) Ab initio methods in quantum chemistry. Advances in Chemical Physics, Vols 67 and 68, Wiley Interscience, New York.
Ashford, J.W., Sherman, K.A. and Kumar, V. (1989) Advances in Alzheimer therapy: cholinesterase inhibitors. Neurobiol. Aging 10, 99-105.
Bartlett, P.A. and Holmes, C.P. (1983) A highly stereoselective synthesis of davanone. Tetrahedron Lett. 24, 1365-1368.
Batt, J.P., Lamouri, A., Tavet, F., Heymans, F., Dive, G. and Godfroid, J.J. (1991) New hypothesis on the conformation of the PAF-receptor from the studies on the geometry of selected platelet-activating factor-antagonists. J. Lipid Mediators 4, 343-346.
Bazan, N. (1994) Platelet-activating factor is a synapse messenger and an intracellular modulator of gene expression. J. Lipid Mediators. 10, 83-86.
Bazan, N. and Cluzel, J. (1992) Membrane-derived lipid second messengers as targets for neuroprotection: Platelet-activating factor. In Marangos, P. and LaI, H. et al. (Eds), Emerging Strategies in Neuroprotection. Birkhailser, Boston, pp. 238-251.
Bazan, N.G., Squinto, S.P., Braquet, P., Panetta, T. and Marcheselli, V.L. (1991) Platelet-activating factor and polyunsaturated Fatty acids in cerebral ischemia or convulsions: Intracellular PAF-binding sites and activation of a FOS/JUN/AP-1 transcriptional signaling system. Lipids 26, 1236-1242.
Born, G.V.R. and Cross, M.J. (1963) The aggregation of blood platelets. J. Physiol. 168, 178-195.
Favre, E., Heymans, F., Redeuilh, C., Batt, J.-P., Massicot, F., Blavet, N., Braquet, P. and Godfroid, J.-J. (1992) Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans. J. Lipid Mediators 5, 23-40.
Furno-de Winter, A., Broquet, C., Haelters, J.P., Massicot, F., Sturtz, G. and Godfroid, J.J. (1991) Structure-activity relationships in platelet-activating factor (PAF). 5. Synthesis and in vitro antagonistic activities of ketophosphonates. J. Lipid Mediators 3, 289-300.
Godfroid, J.-J. and Braquet, P. (1986) Quantitative SAR study of PAF-acether isosteres. Trends. Pharmacol. Sci. 7, 368-373.
Godfroid, J.-J., Broquet, C., Jouquey, S., Lebbar, M., Heymans, F., Redeuilh, C., Steiner, E., Michel, E., Coëffier, E., Fichelle, J. and Worcel, M. (1987) Structure-activity relationships in PAF-acether. 3. Hydrophobic contribution to agonistic activity. J. Med. Chem. 30, 792-797.
Godfroid, J.-J. and Dive, G. (1990) PAF receptor agonists: structure-activity relationships. In Handley, D., Saunders, R., Houlihan W. and Tomesch, J. (Eds), Platelet-Activating Factor in Endotoxin and Immune Diseases, Dekker, New York, pp. 15-30.
Godfroid, J.J., Dive, G., Lamotte-Brasseur, J., Batt, J.P. and Heymans, F. (1991) PAF receptor ztructure: A hypothesis. Lipids 26, 1162-1166.
Hansch, C. and Hockman, D. (1995) Exploring QSAR, hydrophobic, electronic and steric constants, ACS Professional Reference Book, American Chemical Society, Washington, DC.
Heymans, F., Lamouri, A., Batt, J.-P., Dive, G. and Godfroid, J.-J. (1994) Design and modelling of new PAF antagonists: 1,4-bis-(3′,4′,5′-trimethoxybenzoyl)-2-substituted carbonyloxymethyl piperazines. J. Lipid Mediators. 10, 153-154.
Houlihan, W.J. (1990) Platelet activating factor antagonists. In Houlihan, W.J. (Ed.), Platelet Activating Factor in Endotoxin and Immune Disease. Dekker, New York, pp. 31-75.
Kajihara, A., Komooka, H., Kamiya, K., Yoneda, T., Yoneda, S., Nakamura, M., Shimizu, T. and Umeyama, H. (1994) Three-dimensional model of the human PAF receptor. J. Lipid Mediators 9, 185-196.
Kenneth, B. and Saeggebarth, K. (1957) The mechanisms of permanganate oxidation. IV. Hydroxylation of olefins and related reactions. J. Am. Chem. Soc. 79, 2822-2824.
Lamotte-Brasseur, J., Dive, G., Lamouri, A., Heymans, F. and Godfroid, J.J. (1991) PAF-receptor. III. Conformational and electronic properties of PAF-like agonists and antagonists. Biochim. Biophys. Acta 1085, 91-105.
Lamouri, A., Heymans, F., Tavet, F., Dive, G., Batt, J.P., Blavet, N., Braquet, P. and Godfroid, J.J. (1993) Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3′,4′,5′-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines. J. Med. Chem. 36, 990-1000.
Le Texier, L., Favre, E.. Godfroid J.-J. and S. Halut Desportes (1995) Structure of 5-(3,4,5-trimethoxyphenyl)-2-iodomethyl tetrahydrofuran: A precursor of acetylcholinesterase inhibitors with platelet-activating factor antagonistic activity. Acta Crystallogr. B51, 863-867.
Ninomiya, K., Shioiri, T. and Yamada, S. (1974) Phosphorus in organic synthesis-VII diphenyl phosphorazidate (DPPA). A new convenient reagent for a modified Curtius. Tetrahedron 30, 2151-2157.
Ostermann, G., Hoffmann, B., Ketscher, H.-P. and Till, V. (1991) PAF-agonistic and antagonistic behaviour of new synthetic ether phospholipids. II. Relationships between chemical structure and inhibition of PAF-induced human platelet activation. J. Lipid Mediators 3, 225-237.
Rekker, R.F. (1977) The hydrophobic fragmental constant. In Nanka, W.T. and Rekker, R.F. (Eds), Pharmacochemistry Library, Elsevier, Amsterdam, p. 152.
Rekker, R.F. and De Koort, M.M. (1979) The hydrophobic fragmental constant; extension to a 1.000 data point set. Eur. J. Med. Chem-Chim. Ther. 14, 479-488.
Sternberg, M., Hayes, F., Russell, A., Thomas, P. and Fersht, A. (1987) Prediction of electrostatic effects of engineering of protein charges. Nature 330, 86-88.
Taylor, P. (1985) Anticholinesterase agents. In Gilman, A., Goodman, L. and Murad, F. (Eds), Pharmacological Basis of Therapeutics, MacMillan, New York, pp. 110-129.
Terashita, Z., Tsushima, S., Yoshioka, Y., Nomura, H., Inada, Y. and Nishikawa, K. (1983) CV 3988, a specific antagonist of PAF. Life. Sci. 32, 1975-1982.
Wichrowski, B., Jouquey, S., Broquet, C., Heymans, F., Godfroid, J.-J. and Worcel, M. (1988) Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres. J. Med. Chem. 31, 410-415.
